| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.76▼ | 5.76▼ | 5.77▼ | 5.87▼ | 5.66▲ |
| MA10 | 5.77▼ | 5.79▼ | 5.91▼ | 5.72▲ | 5.37▲ |
| MA20 | 5.76▼ | 5.93▼ | 5.97▼ | 5.56▲ | 5.34▲ |
| MA50 | 5.77▼ | 5.92▼ | 5.75▼ | 5.30▲ | 5.20▲ |
| MA100 | 5.92▼ | 5.74▲ | 5.65▲ | 5.46▲ | 3.45▲ |
| MA200 | 5.98▼ | 5.62▲ | 5.38▲ | 5.65▲ | 5.27▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.028▼ | -0.050▼ | 0.034▲ | 0.043▲ |
| RSI | 44.109▼ | 38.650▼ | 44.274▼ | 54.975▲ | 53.461▲ |
| STOCH | 22.262 | 10.110▼ | 10.622▼ | 70.558 | 69.153 |
| WILL %R | -85.714▼ | -93.878▼ | -94.000▼ | -48.519 | -27.168 |
| CCI | -47.380 | -61.157 | -106.696▼ | 100.310▲ | 159.645▲ |
| MA | $IMRX Price Crossed Below MA(7) | Set Alert |
|
Wednesday, April 22, 2026 02:10 PM
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that ...
|
|
Tuesday, April 21, 2026 02:46 PM
New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation ...
|
|
Monday, April 20, 2026 05:59 AM
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/04/26 | 6.07 | 6.21 | 5.72 | 5.75 | 716,194 |
| 24/04/26 | 6.17 | 6.22 | 5.815 | 6.04 | 730,421 |
| 23/04/26 | 5.88 | 6.15 | 5.795 | 6.13 | 930,915 |
| 22/04/26 | 5.59 | 5.915 | 5.51 | 5.89 | 894,117 |
| 21/04/26 | 5.52 | 5.715 | 5.47 | 5.55 | 722,627 |
| 20/04/26 | 5.635 | 5.68 | 5.2775 | 5.53 | 709,427 |
| 17/04/26 | 5.73 | 5.85 | 5.5001 | 5.56 | 795,614 |
| 16/04/26 | 5.75 | 5.755 | 5.43 | 5.57 | 1,044,578 |
| 15/04/26 | 5.44 | 5.75 | 5.2513 | 5.75 | 893,606 |
| 14/04/26 | 5.75 | 5.83 | 5.39 | 5.41 | 994,042 |
|
|
||||
|
|
||||
|
|